|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-4-7
|
|
pubmed:abstractText |
Whether the prostate-specific antigen (PSA) response to salvage hormonal therapy can act as an intermediate end point for prostate cancer-specific mortality (PCSM) remains unclear. Therefore, we evaluated whether PSA response, defined as the absolute value of the ratio of the rate of PSA change after salvage hormonal therapy to the rate of PSA change before salvage therapy, is associated with the time to PCSM following salvage hormonal therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
7
|
|
pubmed:volume |
96
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
509-15
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15069112-Adult,
pubmed-meshheading:15069112-Aged,
pubmed-meshheading:15069112-Aged, 80 and over,
pubmed-meshheading:15069112-Androgen Antagonists,
pubmed-meshheading:15069112-Antineoplastic Agents, Hormonal,
pubmed-meshheading:15069112-Clinical Trials as Topic,
pubmed-meshheading:15069112-Databases, Factual,
pubmed-meshheading:15069112-Follow-Up Studies,
pubmed-meshheading:15069112-Humans,
pubmed-meshheading:15069112-Male,
pubmed-meshheading:15069112-Middle Aged,
pubmed-meshheading:15069112-Neoplasm Staging,
pubmed-meshheading:15069112-Neoplasms, Hormone-Dependent,
pubmed-meshheading:15069112-Orchiectomy,
pubmed-meshheading:15069112-Predictive Value of Tests,
pubmed-meshheading:15069112-Prognosis,
pubmed-meshheading:15069112-Proportional Hazards Models,
pubmed-meshheading:15069112-Prostate-Specific Antigen,
pubmed-meshheading:15069112-Prostatic Neoplasms,
pubmed-meshheading:15069112-Salvage Therapy,
pubmed-meshheading:15069112-Time Factors,
pubmed-meshheading:15069112-Treatment Failure,
pubmed-meshheading:15069112-Tumor Markers, Biological,
pubmed-meshheading:15069112-United States
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA 02115, USA. adamico@lroc.harvard.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
